312583-37-2Relevant academic research and scientific papers
Imidazole analogues of resveratrol: Synthesis and cancer cell growth evaluation
Bellina, Fabio,Guazzelli, Nicola,Lessi, Marco,Manzini, Chiara
, p. 2298 - 2305 (2015/03/30)
Novel trans-restricted analogues of resveratrol in which the C-C double bond of the natural derivative has been replaced by diaryl substituted imidazole analogues have been designed. The syntheses of 1,4-, 2,4-, and 2,5-diarylimidazoles, in which the two
UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS
-
Page/Page column 29, (2015/02/25)
There is provided a compound having Formula I:(I) wherein: R1 is aryl which is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy, or R1 is aryl which is substituted with a second aryl group or an aryloxy group, wherein the second aryl group or the aryloxy group is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy; R2 is C1-4 alkyl; R3 is selected from hydroxyl and OSO2CH3; R4 and R5 are independently selected from hydrogen, hydroxyl and halogen; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; wherein when R3 is hydroxyl and R4 and R5 are not hydroxyl, the optionally substituted aryl group, second aryl group or aryloxy group of R1 is substituted with one or more hydroxyl groups or C1-4 alkoxy groups, or wherein when R3 is hydroxyl, one of R4 and R5 is hydroxyl, provided that the compound is not N-(1-benzylpiperidin-4-yl)-4-(3,4-dihydroxyphenyl)-N-methyl-1H-imidazole-1-carboxamide hydrobromide. The compound may be used as an inhibitor of fatty acid amide hydrolase.
Carbon-14 labeling of a potential new immunoregulant agent
McEvoy Egan,Dean,Marks,Song, Zhiguo,Melillo
, p. 1095 - 1105 (2007/10/03)
A carbon-14 labeled version of the ascomycin analog 1, a potential new immunosuppressant agent, was synthesized for utilization in animal and human drug metabolism studies. In order to place the carbon-14 label at a metabolically stable position, it was n
Highly chemoselective trichloroacetimidate-mediated alkylation of ascomycin: A convergent, practical synthesis of the immunosuppressant L- 733,725
Song, Zhiguo,DeMarco, Anthony,Zhao, Mangzhu,Corley, Edward G.,Thompson, Andrew S.,McNamara, James,Li, Yulan,Rieger, Dale,Sohar, Paul,Mathre, David J.,Tschaen, David M.,Reamer, Robert A.,Huntington, Martha F.,Ho, Guo-Jie,Tsay, Fuh-Rong,Emerson, Khateeta,Shuman, Richard,Grabowski, Edward J. J.,Reider, Paul J.
, p. 1859 - 1867 (2007/10/03)
L-733,725, a new immunosuppressant drug candidate, was prepared by a highly chemoselective alkylation of the macrolide ascomycin at the C32 hydroxy position with the imidazolyl trichloroacetimidate 16. The trichloroacetimidate-activated side chain 16 was prepared by an efficient fourstep sequence in 42% overall yield. The high chemoselectivity in the alkylation of the C32 hydroxy group of the unprotected ascomycin was the result of the synergetic effects of the electron-donating protecting group on the imidazole 16, the polar, moderately basic solvent, and the strong acid catalyst. N,N-Dimethylpivalamide mixed with acetonitrile was found to be the best solvent and trifluromethanesulfonic acid the best catalyst. This synthesis coupled with a resin column purification of L-733,725 followed by crystallization of its tartrate salt has been used to make multikilogram quantities of the bulk drug with consistent and high purity.
